AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with Faslodex combined with a placebo in a Phase 3 trial in advanced hormone receptor-positive breast cancer.
The Anglo-Swedish pharma giant
AZN,
AZN,
said the trial met both primary endpoints of improving progression-free survival in the overall patient population and in a prespecified biomarker subgroup of patients whose tumors had qualifying alterations.
The trial will continue to assess overall survival as a key secondary endpoint, it said.
Breast cancer is the most common cancer in the world with an estimated 2.3 million patients diagnosed in 2020.
Write to Kyle Morris at kyle.morris@dowjones.com
